{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:43:27Z","timestamp":1781070207865,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T00:00:00Z","timestamp":1316390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>B lymphoblastic leukaemia (B\u2010ALL) cells are characterized by the expression of various B\u2010cell antigens. Expression of T\/Natural Killer\u2010cell antigens, however, has rarely been reported in B\u2010ALL (TAg+ B\u2010ALL), and the significance of this aberrant antigen expression is unclear. We thus analysed the frequency of TAg+ B\u2010ALL at our institution and investigated its significance in the context of immunophenotypes, cytogenetic\/molecular findings, and prognosis. We reviewed 134 consecutive cases of B\u2010ALL and found 18 cases (13\u00b74%) of TAg+ B\u2010ALL. The most common aberrant T\u2010cell antigens expressed were CD2, CD5, and CD7 at equivalent rates (each in six cases), CD4 (two cases), and CD56 (three cases). Adverse cytogenetic abnormalities were seen in a significantly larger proportion of the TAg+ cases (72\u00b72%) than the TAg\u2212 cases (32\u00b72%; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7003). Multivariate Cox\u2010regression analysis showed that the risk of relapse over time was higher in the TAg+ cases, independent of high risk status (based on age and white blood cell count) and the presence of adverse cytogenetic abnormalities (hazard ratio\u2003=\u20032\u00b7256, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7065). These findings suggest that T\u2010cell antigen expression in B\u2010ALL may be an independent predictor of poor prognosis, and a useful marker to identify patients at increased risk for relapse and for harbouring adverse cytogenetic abnormalities.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08870.x","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T10:30:56Z","timestamp":1316428256000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Aberrant T\u2010cell antigen expression in B lymphoblastic leukaemia"],"prefix":"10.1111","volume":"155","author":[{"given":"Shafinaz","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamraan Z.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony N.","family":"Sireci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana I.","family":"Colovai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foxwell N.","family":"Emmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vundavalli V.","family":"Murty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachir","family":"Alobeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,19]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"310","article-title":"CD5\u2010positive acute lymphoblastic leukemia","volume":"18","author":"Ahmed D.","year":"2008","journal-title":"Journal of College of Physicians and Surgeons Pakistan"},{"key":"e_1_2_7_3_1","unstructured":"Albersten B.K.(2000)Pharmacokinetics of Asparaginase and Antibody Formation in Interfant\u201006. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01025804. NLM Identifier: NCT01025804."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08205.x"},{"key":"e_1_2_7_5_1","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene M.C.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04315.x"},{"key":"e_1_2_7_7_1","unstructured":"Cairo M.(2000)Less intensive therapy for children with non\u2010Hodgkin\u2019s lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00002757?term=NCT00002757&rank=1. NLM Identifier: NCT00002757."},{"key":"e_1_2_7_8_1","first-page":"384","article-title":"Biological and clinical features of B\u2010precursor childhood acute lymphoblastic leukemia showing CD2 and\/or E\u2010rosette co\u2010expression","volume":"77","author":"Cantu\u2010Rajnoldi A.","year":"1992","journal-title":"Haematologica"},{"key":"e_1_2_7_9_1","unstructured":"Dreyer Z.E.(2000)Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00002756?term=acute+lymphoblastic+leukemia+AND+pediatric&rank=29NLM Identifier: NCT00002756."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<224::AID-AJH17>3.0.CO;2-F"},{"key":"e_1_2_7_11_1","first-page":"1015","article-title":"Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T\u2010cell receptor gene patterns","volume":"5","author":"Felix C.A.","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_7_12_1","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.V71.6.1518.1518","article-title":"Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis","volume":"71","author":"Ludwig W.D.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_15_1","unstructured":"Martin P.L.(2000)Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00005585?term=acute+lymphoblastic+leukemia+AND+pediatric&rank=21NLM Identifier: NCT00005585."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200103)66:3<189::AID-AJH1043>3.0.CO;2-A"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2350\/06-03-0057.1"},{"key":"e_1_2_7_18_1","unstructured":"Pieters R.(2000)Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00015873NLM Identifier: NCT00015873."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.252"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07966.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8G5RMTWUEMUU"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903156737"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903370346"},{"key":"e_1_2_7_24_1","volume-title":"ISCN (2009): International System of Human Cytogenetic Nomenclature","author":"Shaffer L.G.","year":"2009"},{"key":"e_1_2_7_25_1","unstructured":"Silverman L.B.(2000a)Treatment of Acute Lymphoblastic Leukemia in Children. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00165178?term=NCT00165178&rank=1NLM Identifier: NCT00165178."},{"key":"e_1_2_7_26_1","unstructured":"Silverman L.B.(2000b)Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00400946NLM Identifier: NCT00400946."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-230656"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<551::AID-MPO23>3.0.CO;2-E"},{"key":"e_1_2_7_29_1","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood.V73.4.1000.1000","article-title":"Biphenotypic leukemic lymphocyte precursors in CD2+ CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues","volume":"73","author":"Uckun F.M.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_7_32_1","first-page":"321","article-title":"Dexamethasone and individualized asparaginase dosing are each associated with superior event\u2010free survival in childhood acute lymphoblastic leukemia: results from DFCI\u2010ALL Consortium Protocol 00\u201001 [abstract]","volume":"114","author":"Vrooman L.M.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_33_1","unstructured":"Winick N.J.(2000)Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00003671?term=acute+lymphoblastic+leukemia+AND+pediatric&rank=58NLM Identifier: NCT00003671."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08870.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08870.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:59:26Z","timestamp":1697392766000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08870.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08870.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08870.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,19]]},"assertion":[{"value":"2011-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}